Cargando…
Mcl-1 stabilization confers resistance to taxol in human gastric cancer
Taxol has been extensively used as an antineoplastic drug to treat human gastric cancer. However, the acquired drug resistance invariably develops and greatly limits the therapeutic efficacy of Taxol. Identification of the underlying resistance mechanisms may inform the development of new therapies...
Autores principales: | Shuang, Wu, Hou, Lili, Zhu, Yan, Li, Qun, Hu, Wanglai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669943/ https://www.ncbi.nlm.nih.gov/pubmed/29137317 http://dx.doi.org/10.18632/oncotarget.20222 |
Ejemplares similares
-
Effects of taxol resistance gene 1 on the cisplatin response in gastric cancer
por: Duan, Shuquan, et al.
Publicado: (2018) -
Taxol(®): The First Microtubule Stabilizing Agent
por: Yang, Chia-Ping Huang, et al.
Publicado: (2017) -
Skp2 stabilizes Mcl-1 and confers radioresistance in colorectal cancer
por: Yu, Xinfang, et al.
Publicado: (2022) -
Taxol Crystals Can Masquerade as Stabilized Microtubules
por: Foss, Margit, et al.
Publicado: (2008) -
Warburg effect in chemosensitivity: Targeting lactate dehydrogenase-A re-sensitizes Taxol-resistant cancer cells to Taxol
por: Zhou, Ming, et al.
Publicado: (2010)